To the best of our knowledge, no previous study has demonstrated that a history of PPI use could be an important factor to consider in decision-making about using either ICI alone or ICI plus chemotherapy for patients with advanced NSCLC with high PD-L1 TPS in clinical settings. The gene discussed is CD274; the disease is non-small cell lung carcinoma.